Instead of pursuing novel biological targets, Scape Bio's initial strategy focuses on de-risking its platform. They target GPCRs already clinically validated by existing small-molecule drugs but that suffer from off-target toxicity or selectivity problems. This allows them to prove their mini-protein modality by creating a superior version of a known therapeutic mechanism.

To pioneer treatments in the new field of aging, the company's strategy is to create new combinations from existing products with established human safety profiles. This adheres to a strict "do no harm" principle, significantly reducing the safety risk and regulatory uncertainty inherent in developing entirely new chemical entities for a preventative, long-term indication.

Serenatus Bio develops three distinct drug programs for OCD, acknowledging that no single treatment is universally effective in heterogeneous psychiatric conditions. This multi-asset approach diversifies risk and increases the probability of successfully treating different patient subpopulations.

Autobahn Therapeutics avoids the high failure rate of novel CNS targets. Instead, their strategy combines a biologically validated mechanism (thyroid hormone's effect on depression) with a proprietary prodrug platform that solves its historical limitation—peripheral side effects. This creates a rare combination of a de-risked target and strong IP.

Instead of relying on finding novel targets, a key strategy in neuropsychiatry is to revisit failed compounds that showed efficacy signals. Companies use modern chemistry and delivery to engineer solutions that separate efficacy from the historical liabilities that halted development, turning past failures into new opportunities.

To secure investment in the high-risk neurodegeneration space, companies must avoid significant 'leaps of faith.' A key de-risking factor is applying novel modalities to clinically validated pathways. This provides a stronger scientific foundation than pursuing a completely unproven biological hypothesis, making the venture more compelling to investors.

By focusing on metabolic pathways implicated in CNS disorders by human genetics, Leal can work with well-understood enzymes and targets. This simplifies the development process compared to pursuing novel, poorly understood CNS-specific pathways, providing a clearer path to drug development.

Navigator Medicines challenges the industry's bias for novel mechanisms. Their strategy is to take a well-validated target (anti-TNF) and innovate by solving its known problems—like immune response, formulation, and dosing—to create a best-in-class therapy. This represents a de-risked approach to innovation.

The CEO's team previously developed Zorampic, which failed commercially due to low efficacy and a kidney toxicity warning. This firsthand experience provided a precise roadmap for their next venture: finding a molecule that was significantly more potent and demonstrably free of the same renal safety liabilities.